Amid outcry, KaloBios may jack the drug’s price and make millions off FDA voucher.
Source: In comeback bid, Shkreli’s old company gets OK to buy life-saving drug | Ars Technica
Hearing exposes Turing’s lavish spending, while exec says they’re losing money.
Source: Greed, lies, and Shkreli’s smug “performance”: Lawmakers go ballistic
After firing indicted CEO, company now fights to keep shares listed on NASDAQ.
Source: Martin Shkreli’s other pharma company files for bankruptcy | Ars Technica
Following arrest of CEO, KaloBios loses CFO, accountants, is delisted from Nasdaq.
Source: Martin Shkreli’s other pharma company is dramatically collapsing | Ars Technica
In a Healthcare summit hosted by Forbes on Thursday, Martin Shkreli, the founder and CEO of Turing Pharmaceuticals, admitted he made a mistake by raising the price of a decades-old drug by more than 5,000 percent. But it’s not the mistake you might expect.
Source: Turing’s Martin Shkreli regrets 5,000% price hike—says it wasn’t high enough | Ars Technica
Turing will offer hospitals and patients discounts, but high list price stands.
Source: $750/pill pharma company reverses decision to lower drug price | Ars Technica